Saturday , December 2 2023

Recent Posts

CDC and FDA Expedite the Availability of Additional Doses of new RSV Immunization for Infants

Recently, CDC announced the release of more than 77,000 additional doses of Beyfortus™ (nirsevimab-alip (100 mg), a long-acting monoclonal antibody designed to protect infants against severe respiratory syncytial virus (RSV) disease. These additional doses will be distributed immediately to physicians and hospitals through the Vaccines for Children Program and commercial channels …

Read More »
pub-5127930111112337, DIRECT, f08c47fec0942fa0